Jazz Pharmaceuticals plc has identified fatty acid amide hydrolase (FAAH) inhibitors reported to be useful for the treatment of anxiety, autism spectrum disorders, depression, schizophrenia, substance abuse and dependence, psychosis, parasomnia and trauma and stress related disorders.